Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Classical hematology 2

Conditions

Myeloproliferative Disorders 4Myelodysplastic Syndromes 4Primary Myelofibrosis 3Leukemia, Myeloid, Acute 2Anemia 2beta-Thalassemia 1Hematologic Neoplasms 1

Interventions

luspatercept 2vactosertib 1ibrutinib 1fludarabine phosphate 1Taxes 1Rituximab 1Pluvicto 1Pharmacogenomic Testing 1Observation 1Lenalidomide 1Iron-Dextran Complex 1Holistic Health 1Gemcitabine 1Epoetin Alfa 1Cyclophosphamide 1CT-P10 1Biopsy 1Ascorbic Acid 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anemia × luspatercept × 1 year × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡